Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00326339 | Treatment of Arthritis With Syk Kinase Inhibition (TASKI-1) | PHASE2 | COMPLETED | 189 | — | — | Aug 1, 2006 | Dec 1, 2007 | Apr 20, 2009 | 38 | United States, Mexico |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | R788 50 mg PO bid |
| 2 | EXPERIMENTAL | R788 100 mg PO bid |
| 3 | EXPERIMENTAL | R788 150 mg PO bid |
| 4 | PLACEBO_COMPARATOR | Placebo PO bid |
| Name | Type | Description |
|---|---|---|
| R788 | DRUG | R788 50 mg, 100 mg, or 150 mg PO bid |
| Placebo | DRUG | Placebo PO bid |
Inclusion Criteria: 1. Patients must give written informed consent by signing an IRB-approved Informed Consent Form (ICF) prior to admission to this study. 2. Males and females, 18 to 75 years of age, with active RA for at least 12 months (functional class I-III, e.g., not bed or wheelchair-bound) ...